Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jan;64(1):13–17. doi: 10.1136/jnnp.64.1.13

What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®

W Poewe 1, G Deuschl 1, A Nebe 1, E Feifel 1, J Wissel 1, R Benecke 1, K Kessler 1, A Ceballos-Baumann 1, A Ohly 1, W Oertel 1, G Kunig 1
PMCID: PMC2169893  PMID: 9436721

Abstract

OBJECTIVES—Botulinum toxin injections have become a first line therapeutic approach in cervical dystonia. Nevertheless, published dosing schedules, responder rates, and frequency of adverse events vary widely. The present prospective multicentre placebo controlled double blind dose ranging study was performed in a homogenous group of previously untreated patients with rotational torticollis to obtain objective data on dose-response relations.
METHODS—Seventy five patients were randomly assigned to receive treatment with placebo or total doses of 250, 500, and 1000 Dysport® units divided between one splenius capitis (0, 175, 350, 700 units) and the contralateral sternocleidomastoid (0, 75, 150, 300 units) muscle. Assessments were obtained at baseline and weeks 2, 4,and 8 after treatment and comprised a modified Tsui scale, a four point pain scale, a checklist of adverse events, global assessment of improvement, and a global rating taking into account efficacy and adverse events. At week 8 the need for retreatment was assessed and then the code was unblinded. For those still responding, there was an open follow up until retreatment to assess the duration of effect.
RESULTS—seventy nine per cent reported subjective improvement at one or more follow up visits. Decreases in the modified Tsui score were significant at week 4 for the 500 and 1000 unit groups versus placebo (p<0.05). Additionally positive dose-response relations were found for the degree of subjective improvement, duration of improvement, improvement on clinical global rating, and need for reinjection at eight weeks. A significant dose relation was also established for the number of adverse events overall and for the incidence of neck muscle weakness and voice changes.
CONCLUSION—Magnitude and duration of improvement was greatest after injections of 1000 units Dysport®; however, at the cost of significantly more adverse events. Therefore a lower starting dose of 500 units Dysport® is recommended in patients with cervical dystonia, with upward titration at subsequent injection sessions if clinically necessary.



Full Text

The Full Text of this article is available as a PDF (111.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackie J. D., Lees A. J. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):640–643. doi: 10.1136/jnnp.53.8.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borodic G. E., Ferrante R., Pearce L. B., Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994 Jan;9(1):31–39. doi: 10.1002/mds.870090106. [DOI] [PubMed] [Google Scholar]
  3. Brin M. F., Fahn S., Moskowitz C., Friedman A., Shale H. M., Greene P. E., Blitzer A., List T., Lange D., Lovelace R. E. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2(4):237–254. doi: 10.1002/mds.870020402. [DOI] [PubMed] [Google Scholar]
  4. D'Costa D. F., Abbott R. J. Low dose botulinum toxin in spasmodic torticollis. J R Soc Med. 1991 Nov;84(11):650–651. doi: 10.1177/014107689108401107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gelb D. J., Yoshimura D. M., Olney R. K., Lowenstein D. H., Aminoff M. J. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol. 1991 Apr;29(4):370–376. doi: 10.1002/ana.410290407. [DOI] [PubMed] [Google Scholar]
  6. Greene P., Kang U., Fahn S., Brin M., Moskowitz C., Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990 Aug;40(8):1213–1218. doi: 10.1212/wnl.40.8.1213. [DOI] [PubMed] [Google Scholar]
  7. Jankovic J., Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb;40(2):277–280. doi: 10.1212/wnl.40.2.277. [DOI] [PubMed] [Google Scholar]
  8. Jankovic J., Schwartz K., Donovan D. T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633–639. doi: 10.1136/jnnp.53.8.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lees A. J., Turjanski N., Rivest J., Whurr R., Lorch M., Brookes G. Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. J Neurol. 1992 Jan;239(1):1–4. doi: 10.1007/BF00839202. [DOI] [PubMed] [Google Scholar]
  10. Lorentz I. T., Subramaniam S. S., Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord. 1991;6(2):145–150. doi: 10.1002/mds.870060210. [DOI] [PubMed] [Google Scholar]
  11. Moore A. P., Blumhardt L. D. A double blind trial of botulinum toxin "A" in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):813–816. doi: 10.1136/jnnp.54.9.813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nutt J. G., Muenter M. D., Aronson A., Kurland L. T., Melton L. J., 3rd Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988;3(3):188–194. doi: 10.1002/mds.870030302. [DOI] [PubMed] [Google Scholar]
  13. Poewe W., Schelosky L., Kleedorfer B., Heinen F., Wagner M., Deuschl G. Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J Neurol. 1992 Jan;239(1):21–25. doi: 10.1007/BF00839206. [DOI] [PubMed] [Google Scholar]
  14. Stell R., Thompson P. D., Marsden C. D. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 1988 Jul;51(7):920–923. doi: 10.1136/jnnp.51.7.920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tsui J. K., Eisen A., Calne D. B. Botulinum toxin in spasmodic torticollis. Adv Neurol. 1988;50:593–597. [PubMed] [Google Scholar]
  16. Tsui J. K., Eisen A., Stoessl A. J., Calne S., Calne D. B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986 Aug 2;2(8501):245–247. doi: 10.1016/s0140-6736(86)92070-2. [DOI] [PubMed] [Google Scholar]
  17. Wissel J., Poewe W. Dystonia--a clinical, neuropathological and therapeutic review. J Neural Transm Suppl. 1992;38:91–104. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES